Talaris Therapeutics Alpha and Beta Analysis
| TALSDelisted Stock | USD 2.98 0.10 3.25% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Talaris Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Talaris Therapeutics over a specified time horizon. Remember, high Talaris Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Talaris Therapeutics' market risk premium analysis include:
Beta 0.0046 | Alpha 0.56 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Talaris |
Talaris Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Talaris Therapeutics market risk premium is the additional return an investor will receive from holding Talaris Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Talaris Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Talaris Therapeutics' performance over market.| α | 0.56 | β | 0 |
Talaris Therapeutics Fundamentals Vs Peers
Comparing Talaris Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Talaris Therapeutics' direct or indirect competition across all of the common fundamentals between Talaris Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Talaris Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Talaris Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Talaris Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Talaris Therapeutics to competition |
| Fundamentals | Talaris Therapeutics | Peer Average |
| Return On Equity | -0.42 | -0.31 |
| Return On Asset | -0.23 | -0.14 |
| Current Valuation | (28.92 M) | 16.62 B |
| Shares Outstanding | 42.81 M | 571.82 M |
| Shares Owned By Insiders | 11.90 % | 10.09 % |
| Shares Owned By Institutions | 77.67 % | 39.21 % |
| Number Of Shares Shorted | 340.1 K | 4.71 M |
Talaris Therapeutics Opportunities
Talaris Therapeutics Return and Market Media
The Stock received some media coverage during the period. Price Growth (%) |
| Timeline |
1 | Sale by Ildstad Suzanne of 75001 shares of Talaris Therapeutics | 06/09/2023 |
2 | STOCKHOLDER ALERT The MA Class Action Firm Continues Investigating the Merger CIR, TALS, CHRA, QUOT | 06/29/2023 |
About Talaris Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Talaris or other delisted stocks. Alpha measures the amount that position in Talaris Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Talaris Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Talaris Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Talaris Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Talaris Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Talaris Therapeutics. Please utilize our Beneish M Score to check the likelihood of Talaris Therapeutics' management manipulating its earnings.
| 9th of November 2023 Upcoming Quarterly Report | View | |
| 30th of September 2023 Next Fiscal Quarter End | View |
Build Portfolio with Talaris Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Consideration for investing in Talaris Stock
If you are still planning to invest in Talaris Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talaris Therapeutics' history and understand the potential risks before investing.
| Stocks Directory Find actively traded stocks across global markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |